|
1
|
Wilson JF: Alterations in processes and
priorities needed for new drug development. Ann Intern Med.
145:793–796. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu PY, LeBlanc M and Desai M: False
positive rates of randomized phase II designs. Control Clin Trials.
20:343–352. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kaitin KI: Deconstructing the drug
development process: The new face of innovation. Clin Pharmacol
Ther. 87:356–361. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ashburn TT and Thor KB: Drug
repositioning: Identifying and developing new uses for existing
drugs. Nat Rev Drug Discov. 3:673–683. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Padhy BM and Gupta YK: Drug repositioning:
Re-investigating existing drugs for new therapeutic indications. J
Postgrad Med. 57:153–160. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Campillos M, Kuhn M, Gavin AC, Jensen LJ
and Bork P: Drug target identification using side-effect
similarity. Science. 321:263–266. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Keiser MJ, Setola V, Irwin JJ, Laggner C,
Abbas AI, Hufeisen SJ, Jensen NH, Kuijer MB, Matos RC, Tran TB, et
al: Predicting new molecular targets for known drugs. Nature.
462:175–181. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lamb J, Crawford ED, Peck D, Modell JW,
Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, et
al: The Connectivity Map: Using gene-expression signatures to
connect small molecules, genes, and disease. Science.
313:1929–1935. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sirota M, Dudley JT, Kim J, Chiang AP,
Morgan AA, Sweet-Cordero A, Sage J and Butte AJ: Discovery and
preclinical validation of drug indications using compendia of
public gene expression data. Sci Transl Med. 3:96ra772011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cunningham RF, Israili ZH and Dayton PG:
Clinical pharmacokinetics of probenecid. Clin Pharmacokinet.
6:135–151. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Robbins N, Koch SE, Tranter M and
Rubinstein J: The history and future of probenecid. Cardiovasc
Toxicol. 12:1–9. 2012. View Article : Google Scholar
|
|
12
|
Roch-Ramel F and Guisan B: Renal transport
of urate in humans. News Physiol Sci. 14:80–84. 1999.
|
|
13
|
Terkeltaub R: Update on gout: New
therapeutic strategies and options. Nat Rev Rheumatol. 6:30–38.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rees F, Hui M and Doherty M: Optimizing
current treatment of gout. Nat Rev Rheumatol. 10:271–283. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhu Y, Pandya BJ and Choi HK: Prevalence
of gout and hyperuricemia in the US general population: The
National Health and Nutrition Examination Survey 2007–2008.
Arthritis Rheum. 63:3136–3141. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Quillen DM: Crystal arthropathies:
Recognizing and treating 'the gouch'. Prim Care. 37:703–711. 2010.
View Article : Google Scholar
|
|
17
|
Hamburger M, Baraf HS, Adamson TC III,
Basile J, Bass L, Cole B, Doghramji PP, Guadagnoli GA, Hamburger F,
Harford R, et al: 2011 recommendations for the diagnosis and
management of gout and hyperuricemia. Phys Sportsmed. 39:98–123.
2011. View Article : Google Scholar
|
|
18
|
So A: Developments in the scientific and
clinical understanding of gout. Arthritis Res Ther. 10:2212008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Robertson EE and Rankin GO: Human renal
organic anion transporters: Characteristics and contributions to
drug and drug metabolite excretion. Pharmacol Ther. 109:399–412.
2006. View Article : Google Scholar
|
|
20
|
Enomoto A, Kimura H, Chairoungdua A,
Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T,
Igarashi T, et al: Molecular identification of a renal urate anion
exchanger that regulates blood urate levels. Nature. 417:447–452.
2002.PubMed/NCBI
|
|
21
|
Garyfallos A, Magoula I and Tsapas G:
Evaluation of the renal mechanisms for urate homeostasis in uremic
patients by probenecid and pyrazinamide test. Nephron. 46:273–280.
1987. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Boger WP and Strickland SC: Probenecid
(benemid); its uses and side-effects in 2,502 patients. AMA Arch
Intern Med. 95:83–92. 1955. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Scott JT: Comparison of allopurinol and
probenecid. Ann Rheum Dis. 25(Suppl 6): 623–626. 1966. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stocker SL, Graham GG, McLachlan AJ,
Williams KM and Day RO: Pharmacokinetic and pharmacodynamic
interaction between allopurinol and probenecid in patients with
gout. J Rheumatol. 38:904–910. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun J, Wu Y, Xu H and Zhao Z: DTome: A
web-based tool for drug-target interactome construction. BMC
Bioinformatics. 13(Suppl 9): S72012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Landersdorfer CB, Kirkpatrick CM, Kinzig
M, Bulitta JB, Holzgrabe U, Jaehde U, Reiter A, Naber KG, Rodamer M
and Sörgel F: Competitive inhibition of renal tubular secretion of
ciprofloxacin and metabolite by probenecid. Br J Clin Pharmacol.
69:167–178. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Truong DM, Kaler G, Khandelwal A, Swaan PW
and Nigam SK: Multi-level analysis of organic anion transporters 1,
3, and 6 reveals major differences in structural determinants of
antiviral discrimination. J Biol Chem. 283:8654–8663. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nagle MA, Wu W, Eraly SA and Nigam SK:
Organic anion transport pathways in antiviral handling in choroid
plexus in Oat1 (Slc22a6) and Oat3 (Slc22a8) deficient tissue.
Neurosci Lett. 534:133–138. 2013. View Article : Google Scholar :
|
|
30
|
Sweet DH, Miller DS, Pritchard JB,
Fujiwara Y, Beier DR and Nigam SK: Impaired organic anion transport
in kidney and choroid plexus of organic anion transporter 3 (Oat3
(Slc22a8)) knockout mice. J Biol Chem. 277:26934–26943. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sykes D, Sweet DH, Lowes S, Nigam SK,
Pritchard JB and Miller DS: Organic anion transport in choroid
plexus from wild-type and organic anion transporter 3
(Slc22a8)-null mice. Am J Physiol Renal Physiol. 286:F972–F978.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Strazielle N, Belin MF and Ghersi-Egea JF:
Choroid plexus controls brain availability of anti-HIV nucleoside
analogs via pharmacologically inhibitable organic anion
transporters. AIDS. 17:1473–1485. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hedaya MA and Sawchuk RJ: Effect of
probenecid on the renal and nonrenal clearances of zidovudine and
its distribution into cerebrospinal fluid in the rabbit. J Pharm
Sci. 78:716–722. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Petty BG, Kornhauser DM and Lietman PS:
Zidovudine with probenecid: A warning. Lancet. 335:1044–1045. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wolf DL, Rodríguez CA, Mucci M, Ingrosso
A, Duncan BA and Nickens DJ: Pharmacokinetics and renal effects of
cidofovir with a reduced dose of probenecid in HIV-infected
patients with cytomegalovirus retinitis. J Clin Pharmacol.
43:43–51. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Holodniy M, Penzak SR, Straight TM, Davey
RT, Lee KK, Goetz MB, Raisch DW, Cunningham F, Lin ET, Olivo N, et
al: Pharmacokinetics and tolerability of oseltamivir combined with
probenecid. Antimicrob Agents Chemother. 52:3013–3021. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Perwitasari O, Yan X, Johnson S, White C,
Brooks P, Tompkins SM and Tripp RA: Targeting organic anion
transporter 3 with probenecid as a novel anti-influenza a virus
strategy. Antimicrob Agents Chemother. 57:475–483. 2013. View Article : Google Scholar :
|
|
38
|
Penuela S, Gyenis L, Ablack A, Churko JM,
Berger AC, Litchfield DW, Lewis JD and Laird DW: Loss of pannexin 1
attenuates melanoma progression by reversion to a melanocytic
phenotype. J Biol Chem. 287:29184–29193. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Iglesias R, Locovei S, Roque A, Alberto
AP, Dahl G, Spray DC and Scemes E: P2X7 receptor-Pannexin1 complex:
Pharmacology and signaling. Am J Physiol Cell Physiol.
295:C752–C760. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Clark AK, Staniland AA, Marchand F, Kaan
TK, McMahon SB and Malcangio M: P2X7-dependent release of
interleukin-1beta and nociception in the spinal cord following
lipopolysaccharide. J Neurosci. 30:573–582. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li Z, Peng H, Qin L, Qi J, Zuo X, Liu JY
and Zhang JT: Determinants of 14-3-3σ protein dimerization and
function in drug and radiation resistance. J Biol Chem.
288:31447–31457. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Powell DW, Rane MJ, Chen Q, Singh S and
McLeish KR: Identification of 14-3-3zeta as a protein kinase B/Akt
substrate. J Biol Chem. 277:21639–21642. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Waterman MJ, Stavridi ES, Waterman JL and
Halazonetis TD: ATM-dependent activation of p53 involves
dephosphorylation and association with 14-3-3 proteins. Nat Genet.
19:175–178. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
44
|
Miyazaki H, Anzai N, Ekaratanawong S,
Sakata T, Shin HJ, Jutabha P, Hirata T, He X, Nonoguchi H, Tomita
K, et al: Modulation of renal apical organic anion transporter 4
function by two PDZ domain-containing proteins. J Am Soc Nephrol.
16:3498–3506. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Couet J, Sargiacomo M and Lisanti MP:
Interaction of a receptor tyrosine kinase, EGF-R, with caveolins.
Caveolin binding negatively regulates tyrosine and serine/threonine
kinase activities. J Biol Chem. 272:30429–30438. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shimizu T, Sugiura T, Wakayama T, Kijima
A, Nakamichi N, Iseki S, Silver DL and Kato Y: PDZK1 regulates
breast cancer resistance protein in small intestine. Drug Metab
Dispos. 39:2148–2154. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dallas S, Zhu X, Baruchel S, Schlichter L
and Bendayan R: Functional expression of the multidrug resistance
protein 1 in microglia. J Pharmacol Exp Ther. 307:282–290. 2003.
View Article : Google Scholar : PubMed/NCBI
|
